[Skip to the checklist or briefing](#main) 

B

Berkeley Care Checklist California care in checkboxes

Berkeley, California

Care briefing · Checking a claim

# Look for proof about the exact product

Ask whether the study tested the product you are being offered.

## Start with the product’s status

The agency responsible for medicines at the federal level uses the name Food and Drug Administration, abbreviated FDA.

Compounding is the preparation of medicine, by making or mixing it, for a patient’s particular needs.

BPC-157 and ipamorelin are peptide ingredient names found in online product listings.

Retatrutide is another peptide ingredient sold in products advertised for weight loss.

On September 26, 2026, BPC-157, ipamorelin, and retatrutide had no FDA-approved US product.

That finding alone does not settle whether an ingredient can be used in compounding.

A name alone does not tell you what problem a product is meant to treat. Ask: “Is this being offered for weight, pain, or another problem, and which study in people supports that use?”

FDA’s statement as of September 26, 2026 says federal law forbids compounding with retatrutide or with cagrilintide, another drug ingredient.

- Get the full product and ingredient names.

- Request the exact product’s approval record, or find out who makes it for patients.

- Have the person providing your care explain how approval differs from compounding.

### A directory code is a different thing

In the government’s drug directory, products appear under a number: the National Drug Code, abbreviated NDC.

As of September 26, 2026, a code in that directory did not establish FDA approval.

- If someone shows you an “NDC” number as proof, ask for the separate approval record for that exact product.

- Ask which health problem that approval covers.

- Keep the record with the product name so they can be compared.

## Ask what the research actually tested

Ask the person treating you to connect the study to the treatment they are proposing.

- [ ] Was the work done in people?

- [ ] Did the study test the same ingredient, given the same way: for example, as a pill or a shot?

- [ ] Did it address the same health problem?

- [ ] What was it compared with?

- [ ] Did people feel better, or did only a lab test result change?

- [ ] What did the study leave unanswered?

### A compounded version needs its own explanation

FDA guidance checked September 26, 2026 calls it misleading to claim a compounded drug is proven to match an approved product’s results.

- Ask for a study title and a source you can read.

- Ask whether the study tested this made-to-order medicine or a different drug.

- Ask the person treating you to describe what remains uncertain.

## Source notes

- [FDA: what a drug directory listing means ↗](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory) 

- [FDA: claims about compounded medicines ↗](https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs) 

- [FDA: weight medicines and compounding ↗](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) 

[Next: When to pause →](/risk-brief/) [Back to the start ↑](#main) 

## All care briefings

- [The main checklist](/) 

- [Peptides in plain words](/briefing/) 

- [California licence checks](/at-a-glance/) 

- [Questions for a visit](/question-brief/) 

- [The whole cost](/cost-brief/) 

- [Insurance questions](/coverage-brief/) 

- [Checking a claim](/evidence-brief/) 

- [When to pause](/risk-brief/) 

- [Follow-up and help](/safety-brief/) 

Keep your questions with this guide; this site runs no clinic, and medicine sales are not part of its work.

[Read as plain text](/evidence-brief/index.md) [Text index](/llms.txt)